vs
Brilliant Earth Group, Inc.（BRLT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Brilliant Earth Group, Inc.的1.7倍（$207.3M vs $124.4M），Brilliant Earth Group, Inc.净利率更高（-2.3% vs -62.0%，领先59.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 4.1%），Brilliant Earth Group, Inc.自由现金流更多（$5.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 13.1%）
Brilliant Earth是2005年8月由贝丝·格斯坦与埃里克·格罗斯伯格创立的美国珠宝企业，总部位于加利福尼亚州旧金山，主打标注为合规溯源的钻石与其他宝石珠宝，该品牌推动了 ethical 珠宝市场的发展，2017年曾有媒体对其部分产地来源声明提出质疑。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BRLT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $124.4M | $207.3M |
| 净利润 | $-2.9M | $-128.6M |
| 毛利率 | 55.9% | — |
| 营业利润率 | -0.0% | -54.7% |
| 净利率 | -2.3% | -62.0% |
| 营收同比 | 4.1% | 25.9% |
| 净利润同比 | -908.9% | 3.5% |
| 每股收益（稀释后） | $-0.20 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $124.4M | $207.3M | ||
| Q3 25 | $110.3M | $159.9M | ||
| Q2 25 | $108.9M | $166.5M | ||
| Q1 25 | $93.9M | $139.3M | ||
| Q4 24 | $119.5M | $164.6M | ||
| Q3 24 | $99.9M | $139.5M | ||
| Q2 24 | $105.4M | $147.0M | ||
| Q1 24 | $97.3M | $108.8M |
| Q4 25 | $-2.9M | $-128.6M | ||
| Q3 25 | $-107.0K | $-180.4M | ||
| Q2 25 | $-166.0K | $-115.0M | ||
| Q1 25 | $-466.0K | $-151.1M | ||
| Q4 24 | $358.0K | $-133.2M | ||
| Q3 24 | $-141.0K | $-133.5M | ||
| Q2 24 | $185.0K | $-131.6M | ||
| Q1 24 | $139.0K | $-170.7M |
| Q4 25 | 55.9% | — | ||
| Q3 25 | 57.6% | — | ||
| Q2 25 | 58.3% | — | ||
| Q1 25 | 58.6% | — | ||
| Q4 24 | 59.6% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 60.8% | — | ||
| Q1 24 | 59.9% | — |
| Q4 25 | -0.0% | -54.7% | ||
| Q3 25 | -0.6% | -106.9% | ||
| Q2 25 | -1.1% | -64.8% | ||
| Q1 25 | -3.8% | -102.6% | ||
| Q4 24 | 2.0% | -74.3% | ||
| Q3 24 | -1.1% | -94.6% | ||
| Q2 24 | 1.1% | -79.1% | ||
| Q1 24 | 0.9% | -151.9% |
| Q4 25 | -2.3% | -62.0% | ||
| Q3 25 | -0.1% | -112.8% | ||
| Q2 25 | -0.2% | -69.0% | ||
| Q1 25 | -0.5% | -108.5% | ||
| Q4 24 | 0.3% | -80.9% | ||
| Q3 24 | -0.1% | -95.7% | ||
| Q2 24 | 0.2% | -89.5% | ||
| Q1 24 | 0.1% | -156.8% |
| Q4 25 | $-0.20 | $-1.28 | ||
| Q3 25 | $-0.01 | $-1.81 | ||
| Q2 25 | $-0.01 | $-1.17 | ||
| Q1 25 | $-0.03 | $-1.57 | ||
| Q4 24 | $0.02 | $-1.34 | ||
| Q3 24 | $-0.01 | $-1.40 | ||
| Q2 24 | $0.01 | $-1.52 | ||
| Q1 24 | $0.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $79.1M | $421.0M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $12.3M | $-80.0M |
| 总资产 | $200.9M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
| Q4 25 | $79.1M | $421.0M | ||
| Q3 25 | $73.4M | $202.5M | ||
| Q2 25 | $133.6M | $176.3M | ||
| Q1 25 | $147.3M | $127.1M | ||
| Q4 24 | $161.9M | $174.0M | ||
| Q3 24 | $152.7M | $150.6M | ||
| Q2 24 | $152.2M | $480.7M | ||
| Q1 24 | $147.5M | $112.3M |
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $34.5M | — | ||
| Q1 25 | $54.5M | — | ||
| Q4 24 | $55.7M | — | ||
| Q3 24 | $58.1M | — | ||
| Q2 24 | $58.0M | — | ||
| Q1 24 | $58.8M | — |
| Q4 25 | $12.3M | $-80.0M | ||
| Q3 25 | $12.0M | $9.2M | ||
| Q2 25 | $15.3M | $151.3M | ||
| Q1 25 | $14.9M | $144.2M | ||
| Q4 24 | $15.3M | $255.0M | ||
| Q3 24 | $14.5M | $346.8M | ||
| Q2 24 | $14.1M | $432.4M | ||
| Q1 24 | $13.3M | $140.3M |
| Q4 25 | $200.9M | $1.5B | ||
| Q3 25 | $203.0M | $1.2B | ||
| Q2 25 | $260.9M | $1.3B | ||
| Q1 25 | $269.6M | $1.3B | ||
| Q4 24 | $281.2M | $1.5B | ||
| Q3 24 | $273.2M | $1.5B | ||
| Q2 24 | $272.5M | $1.6B | ||
| Q1 24 | $268.2M | $1.3B |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 2.26× | — | ||
| Q1 25 | 3.65× | — | ||
| Q4 24 | 3.63× | — | ||
| Q3 24 | 4.01× | — | ||
| Q2 24 | 4.13× | — | ||
| Q1 24 | 4.43× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $5.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 4.6% | -48.6% |
| 资本支出强度资本支出/营收 | 1.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $5.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $7.2M | $-99.8M | ||
| Q3 25 | $608.0K | $-91.4M | ||
| Q2 25 | $9.1M | $-108.3M | ||
| Q1 25 | $-7.1M | $-166.5M | ||
| Q4 24 | $14.1M | $-79.3M | ||
| Q3 24 | $2.0M | $-67.0M | ||
| Q2 24 | $7.3M | $-77.0M | ||
| Q1 24 | $-5.8M | $-190.7M |
| Q4 25 | $5.7M | $-100.8M | ||
| Q3 25 | $-3.0K | $-92.7M | ||
| Q2 25 | $7.9M | $-110.7M | ||
| Q1 25 | $-7.9M | $-167.8M | ||
| Q4 24 | $11.9M | $-79.5M | ||
| Q3 24 | $674.0K | $-68.6M | ||
| Q2 24 | $6.5M | $-79.0M | ||
| Q1 24 | $-6.4M | $-193.9M |
| Q4 25 | 4.6% | -48.6% | ||
| Q3 25 | -0.0% | -58.0% | ||
| Q2 25 | 7.3% | -66.5% | ||
| Q1 25 | -8.4% | -120.5% | ||
| Q4 24 | 10.0% | -48.3% | ||
| Q3 24 | 0.7% | -49.2% | ||
| Q2 24 | 6.1% | -53.7% | ||
| Q1 24 | -6.5% | -178.2% |
| Q4 25 | 1.2% | 0.5% | ||
| Q3 25 | 0.6% | 0.8% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 0.8% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 0.8% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 39.36× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 39.51× | — | ||
| Q1 24 | -41.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRLT
| US | $120.3M | 97% |
| Non Us | $4.2M | 3% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
